// App-Quantinova.ai

SAT0161 : FLUVASTATIN TREATMENT PREVENTS THE INFLAMMATORY/OXIDATIVE STATUS LINKED TO THE CLINICAL ACTIVITY OF THE DISEASE IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

Researchers

Presenter

  • P. Ruiz-Limon

Principal Investigators

  • C. Perez-Sanchez

  • M.A. Aguirre

  • M.L. Bertolaccini

  • R.M. Carretero

  • A. Rodriguez-Ariza

  • N. Barbarroja

  • M. Khamashta

  • E. Collantes-Estevez

  • M.J. Cuadrado

  • C. Lopez-Pedrera

Medical Centers

  • Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain

  • Lupus Research Unit, St Thomas Hospital, London, United Kingdom

  • Imabis, Malaga, Spain

Locations

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

  • Antiphospholipid syndrome

  • Coronary Artery Disease

  • Venous thrombosis

Biomarkers

  • C-C Motif Chemokine Ligand 2

  • C-X-C motif chemokine ligand 8

  • Glutathione

  • Tumor necrosis factor

  • Vascular endothelial growth factor A

Drug/Treatment

  • Fluvastatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved